Medical Patent News

RSS

Shire receives Paragraph IV Notice Letter from Zydus over filing of ANDA for generic LIALDA

Shire plc, the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter today from Zydus Pharmaceuticals USA, Inc. advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of Shire's 1.2g mesalamine delayed release tablets, LIALDA(R).

29 May 2010

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.

28 May 2010

US District Court dismisses all claims and counterclaims in thalidomide patent cases

Celgene Corporation announced that as a result of Barr Laboratories, Inc., withdrawing its Abbreviated New Drug Application (ANDA) for thalidomide with the US Food and Drug Administration, the US District Court for the District of New Jersey has granted the requested dismissal of all claims and counterclaims in the thalidomide patent cases.

27 May 2010

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, "HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS," which includes coverage of Amira's AM461 DP2 receptor antagonist.

27 May 2010

Silence Therapeutics deepens diverse portfolio of RNAi intellectual property

Silence Therapeutics plc announces the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO).

26 May 2010

Genzyme's suit stays final FDA approval of Watson's generic Renvela ANDA

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market sevelamer carbonate 800mg tablets. Watson's sevelamer carbonate tablet is the generic version of Genzyme's Renvela®. Renvela ® is a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease who are on dialysis.

26 May 2010

Applied Spine Technologies awarded U.S. patents for 'Dynamic Spine Stabilizer' and 'Spring Junction'

Applied Spine Technologies, Inc., a medical device company focused on motion preservation of the lumbar spine, was awarded two new patents by the U.S. Patent and Trademark Office on May 11, 2010.

25 May 2010

YesDTC acquires DRTV marketing rights to patented MediPendant medical alarm device

YesDTC Holdings, Inc., a direct-to-consumer global distributor and marketer of consumer goods and products, announced today, the Company has acquired the rights to market the patented MediPendant™ medical alarm device from Medical Alarm Concepts Holding, Inc. via direct response television (DRTV).

25 May 2010

USPTO issues composition of matter patent for Transave's ARIKACE

Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE™ (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE until October 1, 2026.

25 May 2010

Shrink files patent related to rapid prototyping system for manufacture of Lab-on-a-Chip devices

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications related to its rapid prototyping system for the manufacture of microfluidic chips, or Lab-on-a-Chip (LOC) devices, have been filed.

25 May 2010

Biomagnetics Diagnostics presents new series of videos on world's first handheld Integrated Optical Biosensor

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced the availability of a new series of video taped interviews of CEO, Clayton Hardman where he presents the world's first handheld Integrated Optical Biosensor (IOBS), which was recently licensed under an agreement with Los Alamos National Security LLC.

25 May 2010

MFSI awarded series of new patents for identifying air-borne pathogens

Microfluidic Systems, a privately-held company, announced today it has been awarded a series of new patents covering both the components and integrated systems that perform fully automated sample collection through identification of air-borne pathogens such as bacteria, viruses, and toxins. Patent number 7,705,739 entitled "Integrated Airborne Substance Collection and Detection System" covers a combined instrument in which a detect-to-warn component is integrated with a detect-to-treat system.

25 May 2010

Wolf Medical Supply, I-Flow settle patent dispute on Redi-Flo Infusion Pump

Wolf Medical Supply, Inc. and I-Flow Corporation, a division of Kimberly-Clark Corporation, have settled out of court ending the patent dispute regarding the Redi-Flo™ Infusion Pump.

25 May 2010

Patent applications for Shrink's stem cell research and drug discovery tool StemDisc filed

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications for its stem cell research and drug discovery tool StemDisc have been filed.

24 May 2010

Abviva receives new patent grant notifications for MSA technology

Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.

24 May 2010

Salix announces additional intellectual property protection for rifaximin in treatment of IBS

Salix Pharmaceuticals, Ltd. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,718,608. This patent provides protection until August 2019 for rifaximin, which Salix markets in the United States under the trade names XIFAXAN® (200mg) and XIFAXAN550™ (550mg).

21 May 2010

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Toxcure, LLC, an emerging specialty biopharmaceutical company, today announced the grant of U.S. Patent No. 7,709,440, which provides Toxcure with intellectual property protection for a method of treating various tumors with neurotoxins.

21 May 2010

Biocept granted US patent for cell separation technology using microfluidic device

Biocept, Inc., an emerging leader in rare cell capture, announced today that the U.S. Patent and Trademark Office has issued a patent for Biocept's cell separation technology using a microfluidic device. U.S. patent #7,695,956 entitled "Device for Cell Separation and Analysis and Method of Using" protects Biocept's microflow device to isolate cells from a bodily fluid using a flow path where straight-line flow is interrupted by transverse posts arranged in a random pattern.

21 May 2010

Collegium Pharmaceutical receives Notice of Allowance from USPTO for DETERx technology

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for its patent application "Abuse-Deterrent Drug Formulations", US Patent Application Number 11/149,867. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.

20 May 2010

EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Board of Appeals of the European Patent Office (EPO) has ruled that claims of the Kreutzer-Limmer '945 (EP 1214945) patent meet needed requirements under European patent law. The '945 patent comprises broad claims covering the length and certain structural requirements for siRNAs that are important for advancement of RNAi therapeutics.

20 May 2010

Medical Patent News

Shire receives Paragraph IV Notice Letter from Zydus over filing of ANDA for generic LIALDA

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

US District Court dismisses all claims and counterclaims in thalidomide patent cases

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Silence Therapeutics deepens diverse portfolio of RNAi intellectual property

Genzyme's suit stays final FDA approval of Watson's generic Renvela ANDA

Applied Spine Technologies awarded U.S. patents for 'Dynamic Spine Stabilizer' and 'Spring Junction'

YesDTC acquires DRTV marketing rights to patented MediPendant medical alarm device

USPTO issues composition of matter patent for Transave's ARIKACE

Shrink files patent related to rapid prototyping system for manufacture of Lab-on-a-Chip devices

Biomagnetics Diagnostics presents new series of videos on world's first handheld Integrated Optical Biosensor

MFSI awarded series of new patents for identifying air-borne pathogens

Wolf Medical Supply, I-Flow settle patent dispute on Redi-Flo Infusion Pump

Patent applications for Shrink's stem cell research and drug discovery tool StemDisc filed

Abviva receives new patent grant notifications for MSA technology

Salix announces additional intellectual property protection for rifaximin in treatment of IBS

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Biocept granted US patent for cell separation technology using microfluidic device

Collegium Pharmaceutical receives Notice of Allowance from USPTO for DETERx technology

EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News